On the other hand, the limited span of the distribution of TRH-DE activity in the periphery opens the possibility that inhibition of median eminence TRH-DE activity may be an interesting target for treatment of hypothyroidism and may have few non-intended targets, if a compound that does not pass the blood-brain barrier is chosen. The gene discussed is TRH; the disease is hypothyroidism.